CARLSBAD, Calif., May 10, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will present at the
Bank of America Merrill Lynch 2017 Healthcare Conference at
9:20 a.m. Pacific Time on
Wednesday, May 17, 2017 in
Las Vegas, NV.
A live webcast of the presentation will be available on the
"Investors & Media" section of the Ionis website at
www.ionispharma.com. The replay will be available within 48 hours
and will be archived for a limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over three
dozen drugs in development. SPINRAZA™ (nusinersen) is a drug that
has been approved in the U.S. for the treatment of spinal muscular
atrophy (SMA) in pediatric and adult patients. Biogen is
responsible for commercialization of SPINRAZA. Drugs currently in
Phase 3 development include volanesorsen, a drug Ionis is
developing and plans to commercialize through its wholly owned
subsidiary, Akcea Therapeutics, to treat patients with either
familial chylomicronemia syndrome or familial partial
lipodystrophy; and IONIS-TTRRx, a drug Ionis is
developing with GSK to treat patients with TTR amyloidosis. Ionis'
patents provide strong and extensive protection for its drugs and
technology. Additional information about Ionis is available at
www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' financial position and outlook, Ionis' business,
the business of Akcea Therapeutics, Inc., a wholly owned subsidiary
of Ionis, and the therapeutics and commercial potential of Ionis'
technologies and products in development, including SPINRAZA,
IONIS-TTRRx, and volanesorsen. Any statement describing
Ionis' goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of discovering, developing and commercializing drugs that
are safe and effective for use as human therapeutics, and in the
endeavor of building a business around such drugs. Ionis'
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Ionis' forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Ionis'
programs are described in additional detail in Ionis' annual report
on Form 10-K for the year ended December 31,
2016, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other documents
are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis
Pharmaceuticals, Inc. SPINRAZA™ is a trademark of Biogen.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2017-healthcare-conference-300454703.html
SOURCE Ionis Pharmaceuticals